science
Revolution Medicines Reports Pancreatic Cancer Drug Data at ASCO
New results for Revolution Medicines' daraxonrasib were presented at the ASCO conference over the weekend. A pancreatic cancer expert described an emotional reaction after treating patients with the data.
Jun 1, 1:25 PM·1m read1 source
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
New data on Revolution Medicines' pancreatic cancer treatment drew a standing ovation at the ASCO conference held over the weekend immediately prior to June 1, 2026. The results were described as practice-changing in related STAT headlines published May 31, 2026. ” STAT published an article on June 1, 2026, covering the weekend's ASCO presentations.
The piece was written by Biotech Correspondent Meghana Keshavan, who covers biotech and contributes to The Readout newsletter.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
